Dogwood Therapeutics, Inc. · NASDAQ:DWTX
Dogwood Therapeutics — Corporate Update (September 2026)
34 slides from Dogwood Therapeutics's corporate update, September 2026
Slide 1: Advancing First-in-Class, Non-opioid Medicines to Treat Pain and Neuropathy
Advancing First-in-Class, Non- opioid Medicines to Treat Pain and Neuropathy September 2026 NASDAQ: DWTX
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contain
Slide 3: Corporate Snapshot
Corporate Snapshot Headquarters Atlanta, GA Nasdaq DWTX Shares 33,992,553 Outstanding Cash $13.2 million March 31, 2026 Pro forma Analyst Coverage H.C. Wainwright Maxim Group Pipeline History Cancer and Chemotherapy Related Pain Represents A Major Unmet Medical Need Lead Asset Halneuron has Demonstr
Slide 4: Team Introductions
Team Introductions Greg Duncan R. Michael Gendreau MD, PhD Angela Walsh Chairman & CEO Chief Medical Officer Chief Financial Officer Ralph Grosswald Scott Millard Jerry Evarts Senior VP, Operations VP Research VP Mfg Proven Record of Drug Development & Commercial Success 4
Slide 5: Therapeutic Pain and Neuropathy Pipeline
Therapeutic Pain and Neuropathy Pipeline Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 2026 Milestones Halneuron® Injection Chemotherapy Induced Neuropathic Pain (CINP) Fall ’26 P2b Data Readout Fast Track Designation Q4’26 EOP2 FDA Submission General Cancer Pain Completed P2 Study Demons
Slide 6: The Problem: CIPN Patient Journey
The Problem: CIPN Patient Journey Chemotherapy Induced Oncologist Cancer Treatment Pain Specialists Initial Oncologists Represent Market Neuropathy Symptom Onset Considerations Commercial CINP Call Point Development Opportunity Patients Experience • Mild – continue chemo + • Post chemo chronic pain
Slide 7: Moderate-to-Severe CINP Represents a Major Unmet Medical Need
Moderate-to-Severe CINP Represents a Major Unmet Medical Need There are > 3 Million Existing Annual Estimated Burden of 2,003,140 US CINP Patients New Cancer Type Cancer Type New Cases 57.7% Treated of Cancer Patients Breast 313,310 Treated with Chemo Prostate 299,010 Lung 234,580 1,154,658 Colorect
Slide 8: Significant CINP Treatment Market Across 7 Major Markets, Despite No FDA Approved Treatments
Significant CINP Treatment Market Across 7 Major Markets (7MM), Despite No FDA Approved Treatments Total Market Sales ($M) Market Share (%) by Therapy in the 7MM, 2026 3% $1,015B 5% $126 7% 25% $347 14% $542 46% 2025 US EU4/UK Japan SNRI (e.g. duloxetine) Alpha-2-delta (e.g. Lyrica) Opioids Topical
Slide 9: Halneuron CINP Program Overview
Halneuron® CINP Program Overview
Slide 10: Our Solution - Halneuron
Our Solution - Halneuron® Halneuron® is Tetrodotoxin (TTX), a voltage-gated sodium channel blocker and potent small molecule found in puffer fish and several other marine animals (not a peptide or protein) o Prevents or relieves pain by interrupting nerve conduction o Modulates pain transmission in
Slide 11: What are NaV channels
What are NaV channels Voltage gated sodium channels (NaV) comprises a family of integrated membrane proteins that conduct sodium ions from the extracellular space through a cell’s membrane Structurally, they consist of alpha subunits that form a pore in the plasma membrane through which Na ions
Slide 12: NaV isoforms are Differentially Expressed
NaV isoforms are Differentially Expressed There are 9 NaV family members that differ in their structure, regulation and tissue distribution The NaV 1.x family are all expressed in the brain, whereas a few isotypes are also expressed in the periphery NaV 1.5 in cardiac tissue NaV 1.4 in skele
Slide 13: Role of NaV in pain
Role of NaV in pain Voltage gated sodium channels (NaV1.7-1.9) are important in the peripheral signaling of pain NaV1.7 is of particular interest because individuals with NaV1.7 loss of function mutations are congenitally insensitive to the perception of acute and chronic pain Non-central comp
Slide 14: Nav Sodium Channel Signaling
Nav Sodium Channel Signaling Nerve Damage from Chemotherapy Triggers Pain Signaling The Role of Nav Sodium Channels 1.7 1.8 1.9 Nav 1.7 Nav 1.8 Nav 1.9 Critical to setting the Acts as a "dimmer Thought to be depolarization threshold, or amplifier “ involved in cold and therefore the thought to incre
Slide 15: Mammalian Sodium Channel Isoforms
Mammalian Sodium Channel Isoforms Channel TTX Sensitivity Predominant Distribution Nav1.7 EC50 = 24.5 nM PNS (DRG) Nav1.8 EC50 = 60,000 nM PNS (DRG) Nav1.9 EC50 = 40,000 nM PNS (DRG) Nav1.4 EC50 = 25 nM Skeletal Muscle Nav1.5 EC50 = 5,700 nM Heart Nav1.1 EC50 = 6 nM CNS Nav1.2 EC50 = 18 nM CNS Nav1.
Slide 16: Validation of TTX as a potential Best in Class Analgesic
Validation of TTX as a potential Best in Class Analgesic Preclinical studies involving local as well as sub-chronic administration demonstrated analgesic effects in a variety of animal models Multiple clinical studies have been performed with TTX in cancer patients as well as in patients with ch
Slide 17: Halneuron Pain Reduction in Preclinical Paw Withdrawal Model > VX548
Halneuron® Pain Reduction in Preclinical Paw Withdrawal Model > VX548 at all High, Medium and Low Doses 17
Slide 18: Halneuron Efficacy Builds as Evidenced by Higher Pre-Dose Threshold
Halneuron® Efficacy Builds as Evidenced by Higher Pre-Dose Threshold Prior to Future Doses (i.e. D2-0, D3-0, D4-0 and D5-0) 18
Slide 19: Halneuron Demonstrated Statistically Significant Pain Reduction in Phase 2 Study
Halneuron® Demonstrated Statistically Significant Pain Reduction in Phase 2 Study Compared 30 µg BID x 4 days Placebo BID x 4 days A “Responder” was defined as a patient who had a mean reduction in pain intensity of ≥ 30%; or ≥ 50% reduction in opioid use Conclusions Halneuron® treatment demonstrate
Slide 20: Phase 2 CRP Study Demonstrated Durable Pain Relief in Initial Responders
Phase 2 CRP Study Demonstrated Durable Pain Relief in Initial Responders Mean Pain Response For Halneuron® Responders Was 57.7 Days Vs 10.5 Days For Placebo Responders One-in-four (27%) Halneuron® Halneuron® Responders responders had pain relief for >30 days after 4 days of treatment 0 10 20 30 40 5
Slide 21: Phase 2a Achieved Efficacy and Identified Optimal Dose for Phase 2b
Phase 2a Achieved Efficacy and Identified Optimal Dose for Phase 2b Randomized, double-blind, dose-finding, placebo-controlled, multicenter study evaluating efficacy and safety of Halneuron® in CINP patients (n=125) Doses Tested Compared Results sub-Q injections in 30 µg BID x 4 days o 30 µg results
Slide 22: Phase 2b CINP Study De-Risked with Interim Analysis, Robust Statistical Power
Phase 2b CINP Study De-Risked with Interim Analysis, Robust Statistical Power 4 Week Phase 2b Study Primary Objective to explore the safety and efficacy of Halneuron® in the treatment of patients with moderate-to-severe CINP Screening & Randomization Treatment Phase Endpoints (Week 4) Halneuron QD •
Slide 23: Phase 2b Interim Analysis Also Demonstrates Efficacy Signal, Durable Response in Refractory CINP
Phase 2b Interim Analysis Also Demonstrates Efficacy Signal, Durable Response in Refractory CINP Key Highlights (n=97) • Halneuron demonstrating treatment effect versus placebo o Responders exhibit durable treatment pattern o Halneuron treatment effect +/- concomitant pain meds also > placebo o Haln
Slide 24: Halneuron Drop-out rate is <5% with Manageable AE Rates Across CINP Studies
Halneuron® Drop-out rate is <5% with Manageable AE Rates Across CINP Studies CINP-203 Currently Blinded Summary: CINP 201 CINP-201 TTX 30µg QD x 8 days Adverse Event (AE) TTX 30 µg QD x 4 days Placebo x 4 days Combined Drug + Placebo N=25 N (%) N=25 N (%) N=125 (%) Paresthesia oral (tingling or sens
Slide 25: Advantages of New Synthetic Manufacture of Halneuron for Injection
Advantages of New Synthetic Manufacture of Halneuron® 30 ug for Injection • Scalability - synthetic process not limited by raw material availability. Starting material is a common sugar. • Faster and greater control over the manufacturing process. • Absence of bioburden, largest impurity of natural
Slide 26: Halneuron Intellectual Property
Halneuron® Intellectual Property Anticipated Patent Name Type App/Patent # Date Filed Expiry Stable Pharmaceutical Composition of Freeze-Dried 7/14/2004 Composition of Matter 8,124,608 8/4/2028 Tetrodotoxin Powder Use of Sodium Channel Blockers for the Treatment of Neuropathic Pain Developing as a C
Slide 27: Halneuron Offers Potential Relief for Millions Pain Sufferers in the US Alone
Halneuron Offers Potential Relief for Millions Pain Sufferers in the US Alone Mild CINP Diabetic Peripheral ~142,000 New Neuropathy Patients/Annum1 ~716,000 New Patients/Annum2 Halneuron Initial Approval for ~4 Million Moderate-to-Severe CINP Patients in 2030 Chemo Pain Acute Pain Associated Prevent
Slide 28: SP16 IV Therapy
SP16 IV Therapy Chemotherapy Induced Pain & Peripheral Neuropathy (CIPPN) Program Overview
Slide 29: SP16 Mechanism Allows for Healing During Inflammation
SP16 Mechanism Allows for Healing During Inflammation A1AT Target • A1AT (serine protease inhibitor family) regulates proteases to protect SP26 is a safe and natural solution healthy tissue To inflammatory disease • Dysregulated protease activity drives inflammation and tissue damage Anti- inflammat
Slide 30: SP16 LRP1 Agonism Exhibits Potential to Prevent and/or Repair Nerve Damage
SP16 LRP1 Agonism Exhibits Potential to Prevent and/or Repair Nerve Damage Associated Chemotherapy • In collaboration with Dr. Wendy Campana at the *Reparative Function of SP16 University of California San Diego, SP16 was tested for its regenerative effects on neurons By activation of LRP1 dependent
Slide 31: NCI Funded SP16 Research Plan to be Finalized with FDA and Executed at University of VA
NCI Funded SP16 Research Plan to be Finalized with FDA and Executed at University of VA Patient Population SP16 IV Phase 1b Phase 1b Study Endpoints SP16 Low Dose n=8 Up to 32 Metastatic Cancer • SP 16 Safety Patients Experiencing Neuropathy SP16 Mid Dose n=8 SP-16 • SP 16 Prevention of CIPN from th
Slide 32: Open Label Extension Study Design
Open Label Extension Study Design 12 Week Open Label Study 3 Dosing Intervals Interval 1 (E1) Interval 2 (E2) Interval 3 (E3) Injections: Week 1 Injections: Week 5 Injections: Week 10 2 injections: E1a, E1b 2 injections: E2a, E2b 2 injections: E3a, E3b EOS or or or Screen (if not a rollover) 4 injec
Slide 33: A First-in-Class Approach to Pain and Neuropathy
A First-in-Class Approach to Pain and Neuropathy • Neuropathy includes chronic pain, numbness, tingling, and poor coordination, with significant impact on QoL The Problem of • ~7.5 million patients suffer from moderate–to-severe chemotherapy induced peripheral neuropathy (CIPN) Neuropathic Pain • ~3
Slide 34: 2026 Pipeline Milestones
2026 Pipeline Milestones Key 2026 Milestone Estimated Timing FDA Acceptance of Filing of SP16 IND to Advance to Phase 1b CIPN Study April 2026 Global Combination Antiviral License May 2026 Halneuron Maintenance Study Commences (Part II of Phase 2b) May 2026 SP16 Phase 1b Enrollment Begins • 2H
Dogwood Therapeutics — Corporate Update (September 2026) on 6ix